National Bank of Canada’s Inovio Pharmaceuticals INO Stock Holding History

National Bank of Canada’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$64	Sell	58 -41	-41%	-$49	﹤0.01%	3046
2026 Q1	$172	Hold	99	–	–	﹤0.01%	2805
2025 Q4	$172	Buy	99 +58	+141%	+$128	﹤0.01%	2759
2025 Q3	$96	Sell	41 -13	-24%	-$25	﹤0.01%	2777
2025 Q2	$110	Buy	54 +1	+2%	+$2	﹤0.01%	2857
2025 Q1	$86	Sell	53 -1	-2%	-$2	﹤0.01%	2722
2024 Q4	$99	Sell	54 -2	-4%	-$9	﹤0.01%	2797
2024 Q3	$324	Buy	56 +2	+4%	+$16	﹤0.01%	2505
2024 Q2	$464	Hold	54	–	–	﹤0.01%	2572
2024 Q1	$574	Sell	54 -1	-2%	-$9	﹤0.01%	2587
2023 Q4	$371	Hold	55	–	–	﹤0.01%	2610
2023 Q3	$254	Hold	55	–	–	﹤0.01%	2688
2023 Q2	$297	Sell	55 -103	-65%	-$830	﹤0.01%	2653
2023 Q1	$1.56K	Hold	158	–	–	﹤0.01%	2480
2022 Q4	$2.94K	Hold	158	–	–	﹤0.01%	2429
2022 Q3	$3K	Hold	158	–	–	﹤0.01%	2446
2022 Q2	$3K	Hold	158	–	–	﹤0.01%	2537
2022 Q1	$7K	Hold	158	–	–	﹤0.01%	2467
2021 Q4	$9K	Buy	+158	New	+$12.7K	﹤0.01%	2391

Other funds holding INO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

National Bank of Canada's INO Position: Q2 2026 in Review

National Bank of Canada reduced its Inovio Pharmaceuticals (INO) stake by 41% in Q2 2026, selling an estimated $49 and leaving 58 shares worth $64. The position accounts for ﹤0.01% of the portfolio, ranked #3046.

National Bank of Canada first reported a position in INO in Q4 2021 and has held it in 19 quarters since. The position peaked at $9K in Q4 2021. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

National Bank of Canada held 58 shares of Inovio Pharmaceuticals worth $64 as of Q2 2026.
National Bank of Canada sold 41 Inovio Pharmaceuticals shares in Q2 2026, an estimated $49.
Inovio Pharmaceuticals made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #3046 holding.
National Bank of Canada first reported a position in Inovio Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
National Bank of Canada's Inovio Pharmaceuticals position peaked at $9K in Q4 2021.
103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.